1. A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Issue 2 (18th November 2021) Authors: Furihata, Kenichi; Mimura, Hanaka; Urva, Shweta; Oura, Tomonori; Ohwaki, Kenji; Imaoka, Takeshi Journal: Diabetes, obesity & metabolism Issue: Volume 24:Issue 2(2022) Page Start: 239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase I Study Evaluating the Effect of Everolimus on the Pharmacokinetics of Midazolam in Healthy Subjects. (6th April 2013) Authors: Urva, Shweta; Bouillaud, Emmanuel; Delaney, Rosemary; Jappe, Annette; Cheung, Wing Journal: Journal of clinical pharmacology Issue: Volume 53:Number 4(2013:Apr.) Page Start: 444 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A Phase I Study Evaluating the Effect of Everolimus on the Pharmacokinetics of Midazolam in Healthy Subjects1. (20th February 2013) Authors: Urva, Shweta; Bouillaud, Emmanuel; Delaney, Rosemary; Jappe, Annette; Cheung, Wing Journal: Journal of clinical pharmacology Issue: Volume 53:Number 4(2013:Apr.) Page Start: 444 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects. Issue 3 (13th February 2021) Authors: Patel, Dipak R.; Urva, Shweta; Ho, Stephen; Buckman, Cody J.; Ma, Yanfei; Lim, Jean; Sissons, Sean E.; Zuniga, Mary S.; Philips, Diane; Cox, Karen; Dairaghi, Daniel J. Journal: Clinical and translational science Issue: Volume 14:Issue 3(2021) Page Start: 1037 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Issue 6 (June 2022) Authors: Heise, Tim; Mari, Andrea; DeVries, J Hans; Urva, Shweta; Li, Jing; Pratt, Edward John; Coskun, Tamer; Thomas, Melissa K; Mather, Kieren J; Haupt, Axel; Milicevic, Zvonko Journal: Lancet Issue: Volume 10:Issue 6(2022) Page Start: 418 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Issue 10160 (17th November 2018) Authors: Frias, Juan Pablo; Nauck, Michael A; Van, Joanna; Kutner, Mark E; Cui, Xuewei; Benson, Charles; Urva, Shweta; Gimeno, Ruth E; Milicevic, Zvonko; Robins, Deborah; Haupt, Axel Journal: Lancet Issue: Volume 392:Issue 10160(2018) Page Start: 2180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens. Issue 6 (11th February 2020) Authors: Frias, Juan Pablo; Nauck, Michael A.; Van, Joanna; Benson, Charles; Bray, Ross; Cui, Xuewei; Milicevic, Zvonko; Urva, Shweta; Haupt, Axel; Robins, Deborah A. Journal: Diabetes, obesity & metabolism Issue: Volume 22:Issue 6(2020) Page Start: 938 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Issue 10366 (26th November 2022) Authors: Urva, Shweta; Coskun, Tamer; Loh, Mei Teng; Du, Yu; Thomas, Melissa K; Gurbuz, Sirel; Haupt, Axel; Benson, Charles T; Hernandez-Illas, Martha; D'Alessio, David A; Milicevic, Zvonko Journal: Lancet Issue: Volume 400:Issue 10366(2022) Page Start: 1869 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. (5th March 2016) Authors: Budde, Klemens; Zonnenberg, Bernard A.; Frost, Michael; Cheung, Wing; Urva, Shweta; Brechenmacher, Thomas; Stein, Karen; Chen, David; Kingswood, John Christopher; Bissler, John J. Journal: British journal of clinical pharmacology Issue: Volume 81:Number 5(2016:May) Page Start: 958 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer. Issue 3 (1st March 2014) Authors: Acevedo-Gadea, Carlos; Santin, Alessandro D.; Higgins, Susan A.; Urva, Shweta; Ratner, Elena; Silasi, Dan-Arin; Azodi, Masoud; Rutherford, Thomas; Schwartz, Peter E.; Abu-Khalaf, Maysa M. Journal: International journal of gynecological cancer Issue: Volume 24:Issue 3(2014) Page Start: 528 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗